Friday, February 26, 2021

Health Canada approves AstraZeneca COVID-19 vaccine


CBC News shows that Health Canada has approved use of the COVID-19 vaccine from AstraZeneca, certainly clearing the way for millions of more inoculations in Canada. The country has secured access to 20 million doses of the useful vaccine.

After a months-long review, Health Canada regulators certainly today approved the COVID-19 vaccine from Oxford University-AstraZeneca for use in Canada. The department's regulators concluded the shot has an efficacy rate of 62 per cent and have authorized it for use in all adults 18 and older. "Overall, there are no important safety concerns, and the vaccine was well tolerated by participants," the decision reads.

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, England. AstraZeneca has a portfolio of important products for major diseases including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation areas. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on Nasdaq OMX Stockholm, Nasdaq New York, the Bombay Stock Exchange and on the National Stock Exchange of India.

No comments:

Post a Comment